Shengxiang Biotech announced that its four products recently received the “Medical Device Registration Certificate” issued by the State Drug Administration. Among them, the two respiratory “small joint test” products have the advantages of high sensitivity, high specificity, and easy operation, and can issue reports in as fast as 30 minutes. Streptococcus pneumoniae, Haemophilus influenzae, and Mora catarrhalis are the main pathogens of community-acquired pneumonia and respiratory infections in children. Escherichia coli, Acinetobacter baumannii, and stenophilus maltophili are common in patients with hospital-acquired pneumonia and ventilator-associated pneumonia. In addition, the EB virus nucleic acid detection kit has achieved important technical upgrades, improved detection sensitivity, and improved support for various specimen types such as plasma and whole blood. The human CYP3A5 gene polymorphism nucleic acid detection kit is mainly used to guide the clinical dosage regimen of the core anti-rejection drug tacrolimus after transplantation.

Shengxiang Biotech announced that its four products recently received the “Medical Device Registration Certificate” issued by the State Drug Administration. Among them, the two respiratory “small joint test” products have the advantages of high sensitivity, high specificity, and easy operation, and can issue reports in as fast as 30 minutes. Streptococcus pneumoniae, Haemophilus influenzae, and Mora catarrhalis are the main pathogens of community-acquired pneumonia and respiratory infections in children. Escherichia coli, Acinetobacter baumannii, and stenophilus maltophili are common in patients with hospital-acquired pneumonia and ventilator-associated pneumonia. In addition, the EB virus nucleic acid detection kit has achieved important technical upgrades, improved detection sensitivity, and improved support for various specimen types such as plasma and whole blood. The human CYP3A5 gene polymorphism nucleic acid detection kit is mainly used to guide the clinical dosage regimen of the core anti-rejection drug tacrolimus after transplantation.